DIAMYD: A hot cup of Java! :)A cup and a handle if I ever saw one!
Diamyd has been reporting some great news lately: the Diamyd vaccine showing great results in clinical trials conducted in January this year , as well as getting their manufacturing plant ready for production of the vaccine!
Notice the rising trend in a
−0.108EUR
−9.73 MEUR
45.78 KEUR
79.34 M
About DIAMYD MEDICAL AB SER. B
Sector
CEO
Ulf Hannelius
Headquarters
Stockholm
Website
Employees (FY)
25
Founded
1984
ISIN
SE0005162880
FIGI
BBG00LV48760
Diamyd Medical AB engages in the development of pharmaceutical products for the treatment of diabetes and other serious inflammatory diseases. Its pipeline includes Diamyd and Remygen which targets the underlying causes of diabetes, dysfunction, and loss of the pancreatic beta cells. It also develops and invests in stem cell and medical technology. The company was founded by Anders Essen-Moller in 1996 and is headquartered in Stockholm, Sweden.
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange DIAMYD MEDICAL B stocks are traded under the ticker DMN.
Yes, you can track DIAMYD MEDICAL B financials in yearly and quarterly reports right on TradingView.
DMN net income for the last quarter is −2.60 M EUR, while the quarter before that showed −2.86 M EUR of net income which accounts for 9.06% change. Track more DIAMYD MEDICAL B financial stats to get the full picture.
No, DMN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, DMN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade DIAMYD MEDICAL B stock right from TradingView charts — choose your broker and connect to your account.
As of May 5, 2024, the company has 25.00 employees. See our rating of the largest employees — is DIAMYD MEDICAL B on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. DIAMYD MEDICAL B EBITDA is −10.32 M EUR, and current EBITDA margin is −20.64 K%. See more stats in DIAMYD MEDICAL B financial statements.